Marc Better

2.7k total citations
37 papers, 2.0k citations indexed

About

Marc Better is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Marc Better has authored 37 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 15 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Marc Better's work include Toxin Mechanisms and Immunotoxins (11 papers), CAR-T cell therapy research (11 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Marc Better is often cited by papers focused on Toxin Mechanisms and Immunotoxins (11 papers), CAR-T cell therapy research (11 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Marc Better collaborates with scholars based in United States and Australia. Marc Better's co-authors include Arnold H. Horwitz, Chun‐Wei Chang, Randy Robinson, Donald R. Helinski, Gary S. Ditta, Harrison Echols, Adrian Bot, Barbara Lewis, Charles Lu and Robley C. Williams and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Marc Better

37 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marc Better United States 19 1.1k 639 519 500 394 37 2.0k
Richard Beers United States 26 908 0.8× 680 1.1× 387 0.7× 960 1.9× 154 0.4× 34 2.0k
Robert W. Siegel United States 26 1.3k 1.1× 926 1.4× 209 0.4× 313 0.6× 129 0.3× 62 2.2k
G. Simons Netherlands 17 711 0.6× 90 0.1× 303 0.6× 172 0.3× 296 0.8× 23 1.6k
Mahdi Behdani Iran 24 1.1k 1.0× 767 1.2× 274 0.5× 621 1.2× 239 0.6× 136 1.8k
S. V. S. Kashmiri United States 26 808 0.7× 765 1.2× 769 1.5× 990 2.0× 207 0.5× 60 2.1k
Ileana Quinto Italy 26 1.1k 1.0× 182 0.3× 422 0.8× 688 1.4× 111 0.3× 78 2.1k
Arnold S. Dion United States 29 1.1k 1.0× 501 0.8× 270 0.5× 490 1.0× 537 1.4× 75 2.1k
M S Co United States 15 419 0.4× 416 0.7× 145 0.3× 218 0.4× 175 0.4× 17 1.0k
Hans J. de Haard Netherlands 13 1.4k 1.3× 1.6k 2.5× 435 0.8× 637 1.3× 79 0.2× 15 2.3k
Hanmei Xu China 22 1.3k 1.1× 91 0.1× 594 1.1× 392 0.8× 135 0.3× 53 2.4k

Countries citing papers authored by Marc Better

Since Specialization
Citations

This map shows the geographic impact of Marc Better's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Better with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Better more than expected).

Fields of papers citing papers by Marc Better

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Better. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Better. The network helps show where Marc Better may publish in the future.

Co-authorship network of co-authors of Marc Better

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Better. A scholar is included among the top collaborators of Marc Better based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Better. Marc Better is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Locke, Frederick L., John M. Rossi, Sattva S. Neelapu, et al.. (2020). Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. 4(19). 4898–4911. 266 indexed citations
2.
Neelapu, Sattva S., John M. Rossi, Frederick L. Locke, et al.. (2017). PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI‐CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI‐CEL). Hematological Oncology. 35(S2). 262–263. 2 indexed citations
3.
Lowe, Emily, Arianne Perez, Steven A. Rosenberg, et al.. (2016). Abstract 2305: Comparative evaluation of peripheral blood T cells and resultant engineered anti-CD19 CAR T cell products from relapsed/refractory non-Hodgkin's lymphoma (NHL) patients. Cancer Research. 76(14_Supplement). 2305–2305. 1 indexed citations
4.
Lu, Tangying, Robert Somerville, Steven A. Rosenberg, et al.. (2016). A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies. Human Gene Therapy Methods. 27(6). 209–218. 38 indexed citations
5.
Better, Marc. (1996). T‐Cell‐Targeted Immunofusion Proteins from E. coli. Annals of the New York Academy of Sciences. 782(1). 544–554. 3 indexed citations
6.
Better, Marc, Susan L. Bernhard, Robert E. Williams, et al.. (1995). T Cell-targeted Immunofusion Proteins from Escherichia coli. Journal of Biological Chemistry. 270(25). 14951–14957. 9 indexed citations
7.
Horwitz, Arnold H., Rossana Nadell, Frank Preugschat, & Marc Better. (1994). Chimeric immunoglobulin light chains are secreted at different levels: Influence of framework-1 amino acids. Molecular Immunology. 31(9). 683–692. 10 indexed citations
8.
Studnicka, Gary M., et al.. (1994). Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Engineering Design and Selection. 7(6). 805–814. 40 indexed citations
9.
Bernhard, Susan L., Marc Better, Dianne M. Fishwild, et al.. (1994). Cysteine Analogs of Recombinant Barley Ribosome Inactivating Protein Form Antibody Conjugates with Enhanced Stability and Potency in vitro. Bioconjugate Chemistry. 5(2). 126–132. 3 indexed citations
10.
Nolan, Patricia A., et al.. (1993). Cloning and expression of a gene encoding gelonin, a ribosome-inactivating protein from Gelonium multiflorum. Gene. 134(2). 223–227. 28 indexed citations
11.
Fishwild, Dianne M., et al.. (1993). Efficacy of anti-CD5 F(AB′)2 and FAB′ immunoconjugates in human peripheral blood lymphocyte-reconstituted severe combined immunodeficient mice. International Journal of Immunopharmacology. 15(8). 871–878. 4 indexed citations
12.
Better, Marc, Susan L. Bernhard, Shau-Ping Lei, et al.. (1993). Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.. Proceedings of the National Academy of Sciences. 90(2). 457–461. 39 indexed citations
13.
Better, Marc, et al.. (1992). Momordin II, a ribosome inactivating protein fromMomordica balsamina, is homologous to other plant proteins. Nucleic Acids Research. 20(17). 4662–4662. 20 indexed citations
14.
Robinson, Randy, et al.. (1991). Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities. Human Antibodies. 2(2). 84–93. 12 indexed citations
15.
Kotzin, Brian L., Y. K. Chou, John Lafferty, et al.. (1991). Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis.. Proceedings of the National Academy of Sciences. 88(20). 9161–9165. 210 indexed citations
16.
Better, Marc & Arnold H. Horwitz. (1989). [33] Expression of engineered antibodies and antibody fragments in microorganisms. Methods in enzymology on CD-ROM/Methods in enzymology. 178. 476–496. 17 indexed citations
17.
Better, Marc, Chun‐Wei Chang, Randy Robinson, & Arnold H. Horwitz. (1988). Escherichia coli Secretion of an Active Chimeric Antibody Fragment. Science. 240(4855). 1041–1043. 441 indexed citations
18.
Better, Marc, Gary S. Ditta, & Donald R. Helinski. (1985). Deletion analysis of Rhizobium meliloti symbiotic promoters. The EMBO Journal. 4(10). 2419–2424. 73 indexed citations
19.
Stillman, David J., Marc Better, & E. Peter Geiduschek. (1985). Electron-microscopic examination of the binding of a large RNA polymerase III transcription factor to a tRNA gene. Journal of Molecular Biology. 185(2). 451–455. 26 indexed citations
20.
Better, Marc, et al.. (1983). Role of the Xis protein of bacteriophage λ in a specific reactive complex at the attR prophage attachment site. Cell. 32(1). 161–168. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Beers Breakdown of academic impact, for papers by Robert W. Siegel Breakdown of academic impact, for papers by G. Simons Breakdown of academic impact, for papers by Mahdi Behdani Breakdown of academic impact, for papers by S. V. S. Kashmiri Breakdown of academic impact, for papers by Ileana Quinto Breakdown of academic impact, for papers by Arnold S. Dion Breakdown of academic impact, for papers by M S Co Breakdown of academic impact, for papers by Hans J. de Haard Breakdown of academic impact, for papers by Hanmei Xu
Rankless by CCL
2026